Back

Short term effect of Selexipag in comparison to parenteral prostacyclin analogues in pulmonary arterial hypertension patients started on double-combination therapy with ERA and PDE-5 inhibitors

28 August 2020 (08:00 - 18:00)
Organised by:
Congress Presentation Part of: Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure ePosters Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Fabio Dardi

Institute of Cardiology, Bologna (Italy)

62 More presentations in this session

Presentation thumbnail
Shift in transcriptional landscape of human right ventricle in chronic thromboembolic pulmonary arterial hypertension
Ms L. Jafari (Giessen, DE)
Abstract Slides
Presentation thumbnail
Relationship between right ventricular diastolic dysfunction, right atrial phasic function and ventricular filling in pulmonary arterial hypertension
Mr J. Wessels (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Aetiology of sarcoidosis-associated pulmonary hypertension
Mr H. Mathijssen (Nieuwegein, NL)
Abstract Slides
Presentation thumbnail
Pre-operative pulmonary artery pulsatility index does not predict mortality post cardiac transplantation but PVR is a prognostic tool in LVAD-bridged patients.
Doctor N. Bart (Boston, US)
Abstract Slides
Presentation thumbnail
Venous lactate predicts adverse outcomes in normotensive pulmonary embolism
Doctor M. Ebner (Berlin, DE)
Abstract Slides

Access the full session

Session thumbnail
Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure ePosters

The Event

Event poster

ESC Congress 2020

28 August 2020 08:00 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources